Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Prepaid Assets (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Prepaid Assets readings, the most recent being $3.8 million for Q1 2026.

  • On a quarterly basis, Prepaid Assets fell 11.74% to $3.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.8 million, a 11.74% decrease, with the full-year FY2025 number at $2.5 million, down 75.51% from a year prior.
  • Prepaid Assets hit $3.8 million in Q1 2026 for Atara Biotherapeutics, up from $2.5 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $16.0 million in Q3 2022 to a low of $2.4 million in Q2 2025.
  • Median Prepaid Assets over the past 5 years was $9.2 million (2024), compared with a mean of $8.2 million.
  • Biggest five-year swings in Prepaid Assets: surged 63.57% in 2024 and later plummeted 75.51% in 2025.
  • Atara Biotherapeutics' Prepaid Assets stood at $10.3 million in 2022, then crashed by 40.01% to $6.2 million in 2023, then skyrocketed by 63.57% to $10.1 million in 2024, then plummeted by 75.51% to $2.5 million in 2025, then surged by 53.94% to $3.8 million in 2026.
  • The last three reported values for Prepaid Assets were $3.8 million (Q1 2026), $2.5 million (Q4 2025), and $2.8 million (Q3 2025) per Business Quant data.